I-Mab (IMAB)

1.8800 +0.3000 (+18.99%) At close: 04:00PM EDT

I-Mab

2440 Research Boulevard
Suite 400
Rockville, MD 20850
United States
240 745 6330
https://ir.i-mabbiopharma.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 220

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Raj Kannan	CEO & Director	N/A	N/A	1964
Mr. Skelton Joseph	Chief Financial Officer	N/A	N/A	1991
Mr. Tianyi Zhang	Vice President of Investor Relations	N/A	N/A	N/A
Dr. Fernando J. Salle´s Ph.D.	Senior VP and Head of U.S. & EU Business Development	N/A	N/A	N/A
Claire Xu	Head of US site	N/A	N/A	N/A
Dr. Louie Naumovski M.D., Ph.D.	Interim Chief Medical Officer	N/A	N/A	N/A
Mr. Tyler Ehler	Senior Director of Investor Relations	N/A	N/A	N/A

Amounts are as of , and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and internationally. It is developing Uliledlimab, a CD73 neutralizing antibody, which is in Phase 2 clinical trial for the treatment of solid tumors; Givastomig, a bi-specific antibody that is in Phase 1 clinical trial for the treatment of gastric and other cancers; and Ragistomig, a programmed cell death ligand-based tumor-dependent T cell engager, which is in Phase 1 clinical trial for the treatment of for solid tumors. The company is also evaluating opportunities to develop Lemzoparlimab, a fully human CD47 monoclonal antibody for cancer immunotherapy. It has strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell and offer to sell FE301, an interleukin-6 inhibitor. I-Mab was founded in 2014 and is headquartered in Rockville, Maryland.

Corporate governance

I-Mab’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.